Two Sigma Investments, LP Fate Therapeutics Inc Transaction History

Two Sigma Investments, LP

  • $42.3 Billion
  • Q3 2024

A detailed history of Two Sigma Investments, LP transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Two Sigma Investments, LP holds 459,565 shares of FATE stock, worth $1.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
459,565
Previous 1,019,987 54.94%
Holding current value
$1.02 Million
Previous $3.35 Million 51.93%
% of portfolio
0.0%
Previous 0.01%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$3.12 - $5.57 $1.75 Million - $3.12 Million
-560,422 Reduced 54.94%
459,565 $1.61 Million
Q2 2024

Aug 14, 2024
BUY
$3.26 - $7.08 $2.46 Million - $5.35 Million
754,987 Added 284.9%
1,019,987 $3.35 Million
Q1 2024

May 15, 2024
SELL
$3.54 - $8.35 $4.55 Million - $10.7 Million
-1,285,659 Reduced 82.91%
265,000 $1.95 Million
Q4 2023

Feb 14, 2024
SELL
$1.65 - $3.94 $166,011 - $396,415
-100,613 Reduced 6.09%
1,550,659 $5.8 Million
Q3 2023

Nov 14, 2023
SELL
$2.02 - $5.04 $537,871 - $1.34 Million
-266,273 Reduced 13.89%
1,651,272 $3.5 Million
Q2 2023

Aug 14, 2023
BUY
$4.76 - $6.59 $544,839 - $754,304
114,462 Added 6.35%
1,917,545 $9.13 Million
Q1 2023

May 15, 2023
BUY
$4.24 - $11.12 $1.27 Million - $3.33 Million
299,333 Added 19.91%
1,803,083 $10.3 Million
Q4 2022

Feb 14, 2023
BUY
$9.86 - $23.83 $13 Million - $31.3 Million
1,314,683 Added 695.35%
1,503,750 $15.2 Million
Q3 2022

Nov 14, 2022
BUY
$21.04 - $36.06 $3.98 Million - $6.82 Million
189,067 New
189,067 $4.24 Million
Q1 2022

May 16, 2022
SELL
$29.67 - $60.28 $436,149 - $886,116
-14,700 Closed
0 $0
Q4 2021

Feb 14, 2022
SELL
$47.84 - $64.34 $13.6 Million - $18.3 Million
-284,842 Reduced 95.09%
14,700 $860,000
Q3 2021

Nov 15, 2021
BUY
$59.27 - $95.73 $383,299 - $619,085
6,467 Added 2.21%
299,542 $17.8 Million
Q2 2021

Aug 16, 2021
SELL
$67.25 - $92.52 $24.6 Million - $33.9 Million
-366,508 Reduced 55.57%
293,075 $25.4 Million
Q1 2021

May 17, 2021
BUY
$72.16 - $117.4 $24.3 Million - $39.6 Million
337,241 Added 104.62%
659,583 $54.4 Million
Q4 2020

Feb 16, 2021
SELL
$38.09 - $100.95 $1.77 Million - $4.7 Million
-46,582 Reduced 12.63%
322,342 $29.3 Million
Q3 2020

Nov 16, 2020
BUY
$30.41 - $40.5 $4.62 Million - $6.15 Million
151,961 Added 70.04%
368,924 $14.7 Million
Q2 2020

Aug 14, 2020
BUY
$20.21 - $35.23 $4.38 Million - $7.64 Million
216,963 New
216,963 $7.44 Million
Q1 2020

May 15, 2020
SELL
$17.28 - $31.88 $457,608 - $844,246
-26,482 Closed
0 $0
Q4 2019

Feb 14, 2020
SELL
$13.39 - $20.73 $572,275 - $885,979
-42,739 Reduced 61.74%
26,482 $518,000
Q3 2019

Nov 14, 2019
BUY
$15.47 - $22.5 $1.07 Million - $1.56 Million
69,221 New
69,221 $1.08 Million
Q2 2019

Aug 14, 2019
SELL
$15.61 - $20.44 $2.77 Million - $3.63 Million
-177,404 Closed
0 $0
Q1 2019

May 15, 2019
SELL
$13.15 - $18.71 $1.98 Million - $2.82 Million
-150,471 Reduced 45.89%
177,404 $3.12 Million
Q4 2018

Feb 14, 2019
SELL
$11.48 - $16.98 $1.54 Million - $2.28 Million
-134,494 Reduced 29.09%
327,875 $4.21 Million
Q3 2018

Nov 14, 2018
BUY
$8.75 - $16.29 $4.05 Million - $7.53 Million
462,369 New
462,369 $7.53 Million
Q2 2018

Aug 14, 2018
SELL
$9.16 - $13.48 $830,848 - $1.22 Million
-90,704 Closed
0 $0
Q1 2018

May 15, 2018
SELL
$6.3 - $13.77 $503,571 - $1.1 Million
-79,932 Reduced 46.84%
90,704 $885,000
Q4 2017

Feb 14, 2018
BUY
$3.94 - $6.64 $672,305 - $1.13 Million
170,636
170,636 $1.04 Million

Others Institutions Holding FATE

# of Institutions
175
Shares Held
115M
Call Options Held
53.7K
Put Options Held
9K
View Full List

About FATE THERAPEUTICS INC

FATE Quotes by TradingView
  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $215M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email